| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
The precise molecular target of SEP-0371845 has not been extensively characterized in the available literature. It is described as a biochemical compound or biochemical drug. The compound's mechanism of action involves its interaction with specific molecular targets. Further research is needed to fully elucidate its biological targets and pharmacological profile.
|
|---|---|
| ln Vitro |
Biological activity data for SEP-0371845 are limited in the available literature. The compound is primarily characterized as a biochemical reagent for research purposes. Its activity profile has not been extensively reported, and it is not associated with specific in vitro potency values in the available sources. Further studies would be required to characterize its biological activity.
|
| ln Vivo |
In vivo activity of SEP-0371845 has not been reported in the available literature. The compound is used as a biochemical for laboratory research and is not intended for in vivo studies as a drug candidate. Its utility lies in its role as a research tool for biochemical and pharmacological studies.
|
| Enzyme Assay |
SEP-0371845 is used in biochemical assays to study its interaction with specific molecular targets. Typical experimental protocols would involve incubating the compound with target proteins or cells and measuring binding or activity using appropriate detection methods such as fluorescence, radioactivity, or mass spectrometry. Specific assay conditions would depend on the biological system being studied.
|
| Cell Assay |
Cellular activity of SEP-0371845 may be evaluated in relevant cell lines to assess its effects on cellular processes. Cells would be treated with varying concentrations of the compound, and cellular responses would be measured using appropriate assays such as cell viability, proliferation, or signaling pathway activation. Specific protocols would depend on the biological context and the compound's suspected mechanism of action.
|
| Animal Protocol |
In vivo studies are not typically performed with SEP-0371845 as it is a biochemical research tool rather than a drug candidate. The compound is for research use only and not for human use. Its primary application is in laboratory research settings for biochemical and pharmacological investigations.
|
| ADME/Pharmacokinetics |
SEP-0371845 has a molecular formula of C21H19N7 and a molecular weight of 369.42. The compound is stored as powder at -20°C for up to 3 years. In solvent, it can be stored at -80°C for up to 6 months or at -20°C for up to 1 month. The compound is shipped at room temperature for short-term transport. Its complex heterocyclic structure suggests it may have specific physicochemical properties relevant to its biochemical applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for SEP-0371845 are limited, as the compound is a biochemical for research use. It is not intended for human or therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicology profiling is not applicable as the compound is not a drug candidate.
|
| Additional Infomation |
SEP-0371845 is a biochemical compound with a complex structure featuring an imidazo[2,1-f][1,6]naphthyridine core. It has a cyclopropyl group and a dimethyltriazolopyrazine moiety. The compound is used for laboratory research in biochemical and pharmacological studies. Its mechanism of action involves interaction with specific molecular targets. Further research is needed to fully characterize its biological activity and potential applications.
|
| Molecular Formula |
C21H19N7
|
|---|---|
| Molecular Weight |
369.422462701797
|
| Exact Mass |
369.17
|
| Elemental Analysis |
C, 68.28; H, 5.18; N, 26.54
|
| CAS # |
1516896-06-2
|
| PubChem CID |
72709135
|
| Appearance |
Solid powder
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
28
|
| Complexity |
601
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=CN=C(C2=NC(=NN12)[C@H]3C[C@@H]3C4=C(N5C=CC6=C(C5=N4)C=CC=N6)C)C
|
| InChi Key |
ZLHNYULRKIEGAY-HOTGVXAUSA-N
|
| InChi Code |
InChI=1S/C21H19N7/c1-11-10-23-12(2)20-25-19(26-28(11)20)16-9-15(16)18-13(3)27-8-6-17-14(21(27)24-18)5-4-7-22-17/h4-8,10,15-16H,9H2,1-3H3/t15-,16-/m0/s1
|
| Chemical Name |
Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-
|
| Synonyms |
SEP-0371845; SEP 0371845; SEP0371845;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7069 mL | 13.5347 mL | 27.0695 mL | |
| 5 mM | 0.5414 mL | 2.7069 mL | 5.4139 mL | |
| 10 mM | 0.2707 mL | 1.3535 mL | 2.7069 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
